Published On : September 2026
A commercial team assuming that distribution channel preference alone determines how a therapy reaches European patients is skipping the factor that actually determines the route first.
Within the inherited metabolic diseases therapies market, market access route, not channel preference, is what determines whether a therapy moves through standard hospital pharmacy supply or a more specialised distribution path.
This page describes five distribution channels and five business models strictly as market categories, providing no legal, regulatory compliance or reimbursement advice of any kind.
A therapy with full EMA approval and established national reimbursement typically reaches patients through standard hospital pharmacy channels, while one still navigating country-by-country reimbursement negotiation more often relies on compassionate access or direct hospital supply arrangements.
That is why market access and commercial teams experienced in this space plan distribution strategy around expected regulatory and reimbursement timeline, not channel preference alone.
Five distribution channels and five business models complete this report's commercialisation picture, spanning hospital pharmacy, specialty pharmacy, rare disease distribution networks, government procurement and direct hospital supply, and branded orphan drugs, licensed products, specialty distribution, hospital tender-based supply and compassionate access programmes.
For a developer entering a new European country, mapping the expected reimbursement and tender timeline before committing to a specific distribution channel avoids building supply capability around a route that will not actually be viable until national reimbursement clears.
For a hospital or health system, understanding which business model a given therapy falls under clarifies what to expect in terms of pricing negotiation flexibility and long-term supply commitment.
Hospital pharmacy remains the primary distribution channel for therapies requiring in-hospital infusion or specialist administration, particularly enzyme replacement therapy delivered through intravenous or intrathecal routes.
Specialty pharmacy has grown as a distinct channel for therapies suited to subcutaneous or oral administration, reducing the hospital infusion time that intravenous enzyme replacement typically requires.
Both channels require handling capability for temperature-sensitive products, though specialty pharmacy networks increasingly extend that capability closer to a patient's home rather than requiring a hospital visit for every dose.
A hospital pharmacy's capacity to support inherited metabolic disease therapies depends on cold-chain storage, infusion suite availability and staff trained in rare disease administration protocols, capability that is not evenly distributed across every hospital in a national system.
Specialty pharmacy providers increasingly offer home infusion or nurse-visit support for suitable therapies, a service model that extends treatment access beyond the smaller number of hospitals with dedicated metabolic disease infusion capacity.
The choice between hospital pharmacy and specialty pharmacy distribution often depends less on the therapy itself than on a given country's reimbursement structure, since some national systems route high-cost therapies through hospital budgets specifically, effectively channelling supply through hospital pharmacy regardless of a therapy's administration route.
Rare disease distribution networks provide dedicated logistics capability for the small-volume, high-value shipments characteristic of inherited metabolic disease therapies, distinct from general pharmaceutical distribution infrastructure.
Government procurement applies where a national health system centralises purchasing for high-cost therapies, often through a hospital tender process that separates the purchasing decision from individual prescriber choice.
These two channels frequently work together, with a government procurement decision determining which product a rare disease distribution network then delivers to treatment centres nationally.
A rare disease distribution network's value lies in maintaining reliable, temperature-controlled delivery for shipment volumes far smaller than standard pharmaceutical distribution is typically built around, since a single country's total demand for a given ultra-rare therapy can be a handful of patients.
Government procurement processes for inherited metabolic disease therapies increasingly involve multi-year framework agreements rather than single annual purchase decisions, reflecting the long-term, often lifelong nature of treatment for most disease categories this report covers.
Countries with smaller total populations more often rely on a rare disease distribution network shared across several disease categories, rather than building dedicated logistics infrastructure for each individual therapy the way a larger national market can support.
This shared-network approach also means a single logistics disruption can affect supply across several disease categories at once in a smaller market, a concentration risk that a larger national distribution infrastructure spread across more therapies does not carry to the same degree.
|
COMPETITIVE WATCH Government procurement bodies negotiating supply for a small, well-defined patient population increasingly expect a therapy developer to demonstrate distribution reliability across an entire country, not just clinical data, since a missed or delayed shipment for an ultra-rare therapy has an outsized impact on the very small number of patients depending on it relative to a more common condition. |
Branded orphan drugs represent therapies developed and commercialised directly by the originating company, typically carrying EU orphan drug designation and its associated market exclusivity.
Licensed products involve a developer partnering with a regional or national commercialisation specialist to reach markets outside its direct operating footprint, a model several companies operating in this space use to extend reach without building a full pan-European commercial organisation.
Hospital tender-based supply applies where a national or regional procurement body negotiates price and supply terms directly, a model increasingly common for the highest-cost therapy categories.
A branded orphan drug developer retains full control over pricing negotiation and distribution strategy, an advantage in a market this fragmented but one that requires country-by-country regulatory and reimbursement capability many smaller developers do not yet have.
Licensing arrangements let a smaller developer reach patients faster in markets outside its core operating footprint, trading some commercial control for a partner's existing regulatory and distribution relationships.
Specialty distribution, a related but distinct business model, involves a third-party specialist logistics provider handling delivery on behalf of the therapy owner rather than the owner building its own distribution capability, a common choice for developers prioritising speed to market over long-term distribution control.
Compassionate access programmes allow patients to receive a therapy still navigating full EMA approval or national reimbursement, typically for conditions with no existing approved alternative.
These programmes serve a commercial as well as clinical purpose, building physician and patient familiarity with a therapy ahead of its formal market launch.
Compassionate access remains most common for gene therapy and other advanced modalities still completing their European regulatory and reimbursement pathway.
A compassionate access programme typically operates under a more limited distribution footprint than a fully commercialised therapy, often routed through a smaller number of specialist centres willing to manage the additional administrative requirements involved.
For a disease category with no existing approved therapy, a compassionate access programme can be the only treatment access route available to patients for an extended period before formal approval.
Developers running a compassionate access programme typically absorb the therapy's cost during this period, a factor that shapes which developers can sustain such a programme long enough to reach formal approval and reimbursement.
Physicians participating in a compassionate access programme also generate early real-world treatment experience that can inform the therapy's eventual health technology assessment submission, giving the programme a data-generation role alongside its direct patient access function.
European Medicines Agency approval is the first gate a therapy must clear before broad European distribution, though approval alone does not guarantee reimbursement in any individual country.
National reimbursement decisions follow separately in each country, often incorporating a health technology assessment process that evaluates a therapy's value relative to its cost.
Hospital tender systems then determine which specific product a health system purchases where multiple therapies compete for the same disease category, a process this page describes strictly as a market structure rather than offering guidance on how to navigate it.
The gap between EMA approval and full national reimbursement can extend well beyond a year in some European markets, a timing difference that shapes when a therapy actually becomes broadly accessible to diagnosed patients after its formal approval date.
Countries vary in how their health technology assessment process weighs a therapy's cost against a very small treated population, a structural feature of ultra-rare disease reimbursement that this page describes as a market dynamic without offering guidance on any specific national process.
This sequencing, EMA approval first, then separate national reimbursement, then hospital tender participation, means a therapy's presence in one European country says little about its accessibility in another, even where the same EMA approval formally applies across the whole region.
For a market access team, mapping this three-step sequence country by country ahead of a European launch is typically more valuable than a single continent-wide access strategy, given how differently each stage plays out from one national health system to the next.
A therapy that clears EMA approval quickly but faces a slow national reimbursement process in its largest addressable market can end up reaching patients faster in a smaller country with a more streamlined health technology assessment pathway, illustrating why sequencing rather than population size alone often determines early launch geography.
Primarily through hospital pharmacy and specialty pharmacy channels, supplemented by rare disease distribution networks, government procurement and direct hospital supply, depending on a therapy's regulatory and reimbursement status.
A programme allowing patients to receive a therapy still navigating full EMA approval or national reimbursement, typically for conditions with no existing approved alternative.
EMA approval is the first gate a therapy must clear for broad European distribution, but each country then makes its own separate reimbursement decision, often incorporating a health technology assessment process.
A branded orphan drug is commercialised directly by its developer, while a licensed product involves a developer partnering with a regional or national commercialisation specialist to reach markets outside its direct footprint.